Avalo Therapeutics(AVTX)
$7.76+0.06 (+0.78%)
AVTX
Avalo Therapeutics financials statements
$7.76
At close:+0.06 (+0.78%)
Want to see AVTX full AI Analyst Report?
Avalo Therapeutics (AVTX) Ratios
1,100 Followers
Avalo Therapeutics Ratios
AVTX's free cash flow for Q3 2026 was $-11.54M. For the 2026 fiscal year, AVTX's free cash flow was increased by $0.00 and operating cash flow was $-11.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 |
| Quick Ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 |
| Cash Ratio | 1.23 | 19.33 | 1.61 | 0.60 | 2.74 |
| Solvency Ratio | -2.33 | -1.98 | -2.29 | -0.94 | -1.45 |
| Operating Cash Flow Ratio | -3.98 | -7.05 | -6.64 | -1.21 | -3.56 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -4.51 | 0.00 |
| Net Current Asset Value | $ 71.88M | $ 121.19M | $ -5.29M | $ -27.87M | $ 4.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.03 | 0.60 | 0.42 |
| Debt-to-Equity Ratio | 0.03 | 0.00 | 0.07 | -1.83 | 1.44 |
| Debt-to-Capital Ratio | 0.03 | 0.00 | 0.07 | 2.21 | 0.59 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 5.25 | 0.59 |
| Financial Leverage Ratio | 1.40 | 1.13 | 2.87 | -3.06 | 3.48 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -6.82 | -3.69 | -33.58 |
| Interest Coverage Ratio | 0.00 | 0.00 | -8.00 | -8.98 | -34.35 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.41 | 0.19 |
| Interest Debt Per Share | 0.18 | 0.07 | 14.24 | 615.22 | 986.68 |
| Net Debt to EBITDA | 0.17 | 3.84 | 0.30 | -0.18 | 0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 182.99% | 33.26% | 80.98% | 72.38% |
| EBIT Margin | -132362.71% | -7939.91% | -1218.50% | -207.41% | -1521.56% |
| EBITDA Margin | -131779.66% | -7901.59% | -1210.29% | -206.49% | -1490.87% |
| Operating Profit Margin | -123601.69% | -15535.60% | -1421.57% | -207.41% | -1521.56% |
| Pretax Profit Margin | -132362.71% | -7939.91% | -1638.77% | -230.62% | -1566.23% |
| Net Profit Margin | -132642.37% | -7965.76% | -1639.50% | -230.78% | -1563.10% |
| Continuous Operations Profit Margin | -132642.37% | -7965.76% | -1639.50% | -230.78% | -1562.60% |
| Net Income Per EBT | 100.21% | 100.33% | 100.04% | 100.07% | 99.80% |
| EBT Per EBIT | 107.09% | 51.11% | 115.28% | 111.19% | 102.94% |
| Return on Assets (ROA) | -67.20% | -23.31% | -150.26% | -124.85% | -105.19% |
| Return on Equity (ROE) | -94.23% | -26.41% | -431.87% | 381.66% | -365.55% |
| Return on Capital Employed (ROCE) | -70.45% | -47.65% | -167.03% | -332.71% | -136.15% |
| Return on Invested Capital (ROIC) | -70.18% | -47.47% | -161.73% | -211.35% | -134.75% |
| Return on Tangible Assets | -73.86% | -25.05% | -300.68% | -219.74% | -128.30% |
| Earnings Yield | -32.15% | -58.17% | -1248.12% | -87.85% | -47.62% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.72 | 14.15 | 9.41 | 1.12 |
| Payables Turnover | 0.00 | -1.29 | 2.88 | 1.19 | 0.44 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 171.70 | 39.24 |
| Fixed Asset Turnover | 0.13 | 0.36 | 0.98 | 7.49 | 2.00 |
| Asset Turnover | 0.00 | 0.00 | 0.09 | 0.54 | 0.07 |
| Working Capital Turnover Ratio | 0.00 | 0.01 | -2.00 | 1.00 | 0.20 |
| Cash Conversion Cycle | 0.00 | 787.93 | -100.98 | -265.40 | -490.94 |
| Days of Sales Outstanding | 0.00 | 505.70 | 25.80 | 38.80 | 324.50 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 2.13 | 9.30 |
| Days of Payables Outstanding | 0.00 | -282.23 | 126.78 | 306.33 | 824.74 |
| Operating Cycle | 0.00 | 505.70 | 25.80 | 40.93 | 333.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.84 | -6.04 | -110.47 | -682.39 | -1958.83 |
| Free Cash Flow Per Share | -3.84 | -6.04 | -111.04 | -684.81 | -1961.95 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -194.18 | -281.59 | -627.36 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -194.18 | -281.59 | -627.36 |
| Operating Cash Flow Coverage Ratio | -21.20 | -86.37 | -57.13 | -1.34 | -2.13 |
| Operating Cash Flow to Sales Ratio | -872.17 | -111.24 | -15.95 | -1.48 | -13.13 |
| Free Cash Flow Yield | -21.14% | -81.23% | -1220.19% | -56.61% | -40.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.11 | -1.72 | -0.08 | -1.14 | -2.10 |
| Price-to-Sales (P/S) Ratio | 4125.96 | 136.95 | 1.31 | 2.63 | 32.83 |
| Price-to-Book (P/B) Ratio | 2.93 | 0.45 | 0.35 | -4.34 | 7.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.73 | -1.23 | -0.08 | -1.77 | -2.50 |
| Price-to-Operating Cash Flow Ratio | -4.73 | -1.23 | -0.08 | -1.77 | -2.50 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | 0.02 | 0.00 | 0.02 | 0.27 |
| Enterprise Value Multiple | -2.96 | 2.11 | 0.19 | -1.45 | -1.94 |
| Enterprise Value | 230.00M | -73.58M | -4.35M | 54.19M | 155.92M |
| EV to EBITDA | -2.96 | 2.11 | 0.19 | -1.45 | -1.94 |
| EV to Sales | 3898.32 | -166.86 | -2.26 | 3.00 | 28.89 |
| EV to Free Cash Flow | -4.47 | 1.50 | 0.14 | -2.02 | -2.20 |
| EV to Operating Cash Flow | -4.47 | 1.50 | 0.14 | -2.03 | -2.20 |
| Tangible Book Value Per Share | 5.41 | 15.07 | -11.51 | -645.99 | 238.60 |
| Shareholders’ Equity Per Share | 6.20 | 16.37 | 26.30 | -278.43 | 637.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.05 | 6.93 | 460.46 | 149.15 |
| Net Income Per Share | -5.84 | -4.32 | -113.58 | -1062.65 | -2331.41 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.34 | 1.11 | 1.03 |
| Research & Development to Revenue | 848.88 | 118.09 | 7.16 | 1.73 | 11.08 |
| SG&A to Revenue | 388.14 | 39.10 | 5.34 | 1.14 | 4.26 |
| Stock-Based Compensation to Revenue | 230.86 | 13.27 | 1.81 | 0.42 | 1.51 |
| Income Quality | 0.66 | 1.40 | 0.97 | 0.64 | 0.84 |
Currency in USD

